CAR-T
ProductHeard on podcasts recently
CAR-T is a personalized cancer immunotherapy in which a patient’s T cells are genetically engineered to recognize and attack cancer cells.
Discussed inMarkets100%
Rank this week
—
Not in this week’s list
Share of the conversation
—
Reach this week
—
Tone this week
—
Not enough signal yet (fewer than 3 episodes scored).
Share of the conversation
Mentions of CAR-T per 1,000 mentions of anything, 7-day rolling, all podcasts.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 31 | 0.02‰ | 2 |
| Sep 2 | 0.03‰ | 1 |
| Oct 19 | 0.01‰ | 1 |
| Nov 13 | 0.01‰ | 1 |
| Nov 15 | 0.02‰ | 1 |
| Nov 20 | 0.02‰ | 1 |
Who is saying what about CAR-T
Verified quotes from the last 90 days: who made the most claims, and which way they leaned.
- Yaron Werber2 claims on 1 show
“it looks like in vivo car t is is fairly promising”
Biotech Hangout · Nov 6 ↗ - David Friedberg1 claim on 1 show
“for blood cancers like multiple myeloma, the efficacy is incredible with CAR T therapies now.”
All-In with Chamath, Jason, Sacks & Friedberg · Aug 29 ↗
Discussed alongside
Names that come up in the same conversations as CAR-T.
Embed this
Paste this on your site to show CAR-T's current trend:
<iframe src="https://podlume.ai/embed/e/car-t" width="360" height="220" style="border:0" loading="lazy" title="CAR-T on PodLume Trends"></iframe>